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Re: “Comparison of antipseudomonal betalactams for febrile neutropenia empiric
therapy: systematic review and network metaanalysis” by Horita et al.Dear Sir,
We read with interest the recent network meta-analysis pub-
lished by Horita et al. comparing different b-lactams in the empir-
ical treatment of febrile neutropenia (FN) [1]. We consider that the
authors draw debatable conclusions that could encourage unjusti-
ﬁably wide use of imipenem/cilastatin in individuals with FN.
Another meta-analysis, published in 2010 [2] on the same issue,
drew different conclusions, showing lower all-cause mortality
with piperacillin/tazobactam versus cefepime or carbapenems.
Several reasons can explain these different ﬁndings. Most obvi-
ously, some studies included by Horita et al., simply post-dated
Paul et al.; but, perhaps more importantly, the newly available
studies included by Horita et al. are often from high-resistance
countries and often analysed piperacillin/tazobactam, whereas
much of the imipenem/cilastatin data come from relatively old
studies. As resistance varies with place and time, these factors
have major potential impact.
Overall, 15 studies representing 4026 patients and comparing
piperacillin/tazobactam with other antibiotics were included in
Horita et al.’s meta-analysis, but not in that of Paul et al.; ten of
thesewere published since 2010, variously originating from Turkey,
India, Japan, China and Spain. A recent multinational study of bac-
teraemia in individuals undergoing haematopoietic stem cell trans-
plants found signiﬁcantly higher rates of resistance to non-
carbapenem b-lactams among Gram-negative rods (GNRs) isolated
from patients in southeast Europe (55.3%) or China (76%) versus
those in northwest Europe (27.6%) [3]. In this study, 33.9%, 56.5%
and 52.0% of GNR reported from Spain, Turkey and China, respec-
tively, were resistant to non-carbapenem anti-Pseudomonas peni-
cillin b-lactamase inhibitors. In an Indian study, fully 82.7% of
Escherichia coli and 74.3% of Klebsiella spp. isolated from individuals
with cancer were extended spectrum b-lactamase producers [4].
One would expect to see an advantage for imipenem/cilastatin
over other b-lactams at sites with such high rates of resistance,
where empirical treatment with piperacillin/tazobactam may be
insufﬁcient. Basing the approach to FN on local epidemiology is
crucial. In our recent study in haematopoietic stem cell transplant
patients, a half of GNRwere resistant to non-carbapenem b-lactams
[3]; however, the rates in individual countries ranged from 0%
to 100%.DOI of original article: https://doi.org/10.1016/j.cmi.2018.01.020.
https://doi.org/10.1016/j.cmi.2018.01.012
1198-743X/© 2018 European Society of Clinical Microbiology and Infectious Diseases. PuUnderpinning the high rates of resistance among GNRs in some
parts of the world are changes in the global molecular epidemi-
ology, mainly since 2000, notably including the proliferation of
Escherichia coli ST131 and the common co-presence of CTX-M-15
(an extended spectrum b-lactamase) with OXA-1/30 (a sulphone/
clavam-resistant penicillinase) enzymes in this and other Entero-
bacteriaceae. In some European regions, over 50% of bloodstream
E. coli isolates were reported to be resistant to third-generation
cephalosporins in the 2016 WHO Antimicrobial Resistance report
(http://www.euro.who.int/__data/assets/pdf_ﬁle/0005/354434/
WHO_CAESAR_AnnualReport_2017.pdf?ua¼1). Piperacillin/tazo-
bactam may be less effective in this situation and most (19/23) of
these studies assessing piperacillin/tazobactam in Horita et al.’s
meta-analysis were published after 2000.
Ten studies included in Horita et al.’s meta-analysis compared
imipenem/cilastatin to other antibiotics; these included 2156 pa-
tients. Seven of these studies (1496 patients, 70%) were published
between 1990 and 2004, before the global spread of carbapenem-
resistant Enterobacteriaceae. Several countries have, largely since
2007, seen proliferation of carbapenemases, though the predomi-
nant types (KPC, OXA-48, VIM, NDM or IMP) vary with the partic-
ular country.
Thirteen of the 50 studies selected by Horita et al. were pub-
lished between 1990 and 2000. Signiﬁcant changes occurred in
bacterial resistance since 90s to present day. This is a common
problem of network meta-analysis on antibacterials, where efﬁcacy
may change with time and place. In simple language, this means
that one must be very wary of statistical comparison of agents
that were not compared head-to-head in the same time and place.
In the present case, mortality data on imipenem, based on studies
mainly published before the emergence of carbapenem-
resistance, are compared with mortality data on piperacillin/tazo-
bactam based on more recent studies, mainly from countries with
high rates of extended spectrum b-lactamase infections.
Another concern is the dosing regimens of b-lactams, which was
not considered in Horita et al.’s meta-analysis. Individuals with FN
have an increased volume of distribution and increased clearance,
resulting in a decreased time above MIC. Therefore, using a
maximal dosage is crucial. In the studies selected by Horita et al.,
piperacillin/tazobactam was dosed at 4.5 g thrice daily in 6/23
studies and 24% of the patients, and meropenem was dosed at
2 g/day (in adults) in 2/14 studies and 24% of the patients. These
regimens, whichwere not enhanced by prolonged/continuous infu-
sion, may be insufﬁcient.blished by Elsevier Ltd. All rights reserved.
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medications, imipenem/cilastatin was related to the highest treat-
ment success rate and the lowest all-cause death’ may encourage
preferential use of imipenem/cilastatin as the primary choice for
any FN. However, no signiﬁcant differences were reported accord-
ing to the primary end point (treatment success without modiﬁca-
tion) between cefepime, meropenem, imipenem/cilastatin and
piperacillin/tazobactam, nor for a secondary end point (all-cause
death) between meropenem, imipenem/cilastatin, ceftazidime
and piperacillin/tazobactam. Moreover, there are no signiﬁcant dif-
ferences in the spectrum of coverage betweenmeropenem and imi-
penem/cilastatin.
In conclusion, the ECIL groupwishes to reiterate its previous po-
sition that, although we have no doubt as to the efﬁcacy and safety
proﬁle of imipenem/cilastatin in patients with FN, carbapenems
should, whenever possible, be avoided in individuals without se-
vere clinical presentation and risk factors for bacterial resistance
to other agents, so as to preserve their activity [5]. The wide range
of resistance rates among GNRs in different countries warrants a
customized approach in patients with FN, combined with rigorous
infection control in settings where resistance has become or is
becoming prevalent. Universal deployment of carbapenems
without de-escalation in all individuals with FN, half of whom
have neither clinical nor microbiological infection, is only likely to
lead to an increase in carbapenem-resistant infections, and should
be discouraged.
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